Download presentation
Presentation is loading. Please wait.
Published byMaurice Oliver Modified over 9 years ago
1
The TRial Of Preventing HYpertension (TROPHY) TROPHY
2
TROPHY – hypothesis The TRial Of Preventing HYpertension (TROPHY) is an investigator-initiated trial to examine whether early treatment of high-normal blood pressure values (according to JNC VI) with candesartan would prevent or postpone the development of stage 1 hypertension. Julius et al, Hypertension 2004
3
TROPHY – objectives Primary –to determine whether treatment with candesartan 16 mg compared with placebo reduces the incidence of hypertension in subjects with high- normal BP Secondary –evaluate reduction of BP after 2 years of treatment with candesartan 16 mg versus placebo –evaluate incidence of hypertension after 2 years of treatment with candesartan 16 mg versus placebo –evaluate quality of life during 2 years of treatment with candesartan 16 mg versus placebo Julius et al, Hypertension 2004
4
TROPHY– inclusion criteria Aged 30 to 65 years Clinic BP reading of 130-139/ 89 mm Hg or 139/85-89 mm Hg Julius et al, Hypertension 2004
5
TROPHY – study design Two Years Qualifying period * Placebo Non-pharmacological treatment Candesartan cilexetil 16 mg n 400 Placebo * Clinic BP reading of 130-139/ 89 mm Hg or 139/85-89 mm Hg Julius et al, Hypertension 2004
6
TROPHY – end point Development of clinical hypertension –Mean clinic BP by automated device 140/90 mm Hg at 3 different clinic visits during the 4-year study period –Mean clinic BP by automated device 160/100 mm Hg at any single visit during the 4-year study period –Development of signs of target organ damage or a BP condition requiring pharmacological treatment, as judged by the investigator –Mean clinic BP by automated device 140/90 mm Hg at the 48-month visit Julius et al, Hypertension 2004
7
TROPHY – baseline characteristics VariableValue Randomised patients, n809 Male, n482 Female, n326 Age, years49 14 BMI, kg/m 2 30 5 Blood pressure, mmHg Clinic automated134 4/85 4 Clinic regular133 5/85 4 Measured at home134 9/83 10 Julius et al, Hypertension 2004
8
TROPHY: Risk of hypertension after two years with candesartan vs placebo, followed by two years of placebo vs placebo Time point Candesartan, n Placebo, n Relative risk (95% CI)p At two 2 years 5315466.3<0.001 At four 4 years 20824015.6<0.007 Julius S et al. N Engl J Med 2006;available at http://www.nejm.org
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.